1. Home
  2. CGBD vs CGEM Comparison

CGBD vs CGEM Comparison

Compare CGBD & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Carlyle Secured Lending Inc.

CGBD

Carlyle Secured Lending Inc.

HOLD

Current Price

$10.69

Market Cap

826.2M

Sector

Finance

ML Signal

HOLD

Logo Cullinan Oncology Inc.

CGEM

Cullinan Oncology Inc.

HOLD

Current Price

$13.81

Market Cap

904.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CGBD
CGEM
Founded
2012
2016
Country
United States
United States
Employees
2500
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
826.2M
904.7M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
CGBD
CGEM
Price
$10.69
$13.81
Analyst Decision
Hold
Strong Buy
Analyst Count
8
8
Target Price
$12.92
$30.13
AVG Volume (30 Days)
570.6K
881.8K
Earning Date
05-11-2026
05-11-2026
Dividend Yield
14.42%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$3.74
N/A
Revenue Next Year
$1.80
$5.20
P/E Ratio
$10.36
N/A
Revenue Growth
N/A
N/A
52 Week Low
$10.64
$5.68
52 Week High
$14.32
$16.74

Technical Indicators

Market Signals
Indicator
CGBD
CGEM
Relative Strength Index (RSI) 33.31 42.75
Support Level $10.68 $12.41
Resistance Level $12.17 $16.21
Average True Range (ATR) 0.30 0.94
MACD -0.10 -0.16
Stochastic Oscillator 3.80 11.57

Price Performance

Historical Comparison
CGBD
CGEM

About CGBD Carlyle Secured Lending Inc.

Carlyle Secured Lending Inc is a specialty finance company that is a closed-end, externally managed, non-diversified management investment company. It focuses on providing directly originated, financing solutions across the capital structure, with a focus on senior secured lending to middle-market companies located in the United States. The company's investment objective is to generate current income and capital appreciation through debt investments in U.S. middle-market companies.

About CGEM Cullinan Oncology Inc.

Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.

Share on Social Networks: